Full Text View
Tabular View
No Study Results Posted
Related Studies
Tamsulosin Phase III Clinical Trial -Double-Blind, Placebo Controlled Study in Female Patients With Lower Urinary Tract Syndrome
This study has been completed.
First Received: September 13, 2005   Last Updated: October 18, 2007   History of Changes
Sponsor: Astellas Pharma Inc
Information provided by: Astellas Pharma Inc
ClinicalTrials.gov Identifier: NCT00239265
  Purpose

The purpose of this study is to determine whether Tamuslosin is effective in the treatment of lower urinary tract syndrome with female patients.


Condition Intervention Phase
Urinary Tract Diseases
 Drug: Tamuslosin
 Phase III

Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study

Resource links provided by NLM:

Drug Information available for: Tamsulosin Tamsulosin hydrochloride
U.S. FDA Resources
  Eligibility

Ages Eligible for Study:   20 Years to 90 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with urination disorder not accompanied by apparent organic or neurologic abnormality(lower urinary tract syndrome: LUTs)．

Exclusion Criteria:

  • Patients with urination disorder accompanied by apparent organic or neurologic abnormality, active urinary tract infections, severe cardiovascular, hepatic and/or kidney complications.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00239265

Locations
Japan
Hokkaido region, Japan
Touhoku region, Japan
Chubu region, Japan
Kyushu region, Japan
Chugoku region, Japan
Kinki region, Japan
Sponsors and Collaborators
Astellas Pharma Inc
Investigators
Study Chair: Study Director Clinical Development, Astellas Pharma Inc.
  More Information

No publications provided

Study ID Numbers: B6171/LCT2
Study First Received: September 13, 2005
Last Updated: October 18, 2007
ClinicalTrials.gov Identifier: NCT00239265     History of Changes
Health Authority: Japan: Ministry of Health, Labor and Welfare

Keywords provided by Astellas Pharma Inc:
tamsulosin
urinary tract diseases
female

Additional relevant MeSH terms:
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Adrenergic Agents
Urologic Diseases
Antineoplastic Agents
Therapeutic Uses
 Physiological Effects of Drugs
Tamsulosin
Adrenergic Antagonists
Adrenergic alpha-Antagonists
Pharmacologic Actions

ClinicalTrials.gov processed this record on February 08, 2010



Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services